Technical Report No. 56 (Revised 2026) outlines a GMP--compliant, phase--appropriate quality management system (QMS) spanning preclinical development through clinical phases and commercial readiness ...
Bringing a single drug to market can take more than a decade and cost billions of dollars, with fewer than one in ten candidates successfully reaching approval. Against this backdrop, generative AI is ...
Hosted on MSN
FDA to streamline approvals for generic biological drugs in latest move targeting health costs
The U.S. Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...
In my previous article, I discussed how AI is rapidly transforming the drug discovery process, significantly accelerating timelines and reducing costs. However, while AI's potential in this domain is ...
The process of discovering new drugs and bringing them to market is notoriously slow and inefficient. Amazon Web Services is ...
Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...
Organoid screening platforms are transforming drug discovery by providing physiologically relevant 3D models that improve ...
AWS's new AI platform grants researchers direct access to a broad library of biological foundation models for lab-in-the-loop drug discovery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results